Effects of Lentil Protein Hydrolysate on Blood Pressure Control, Vascular Function and Exercise Performance

Launched by NURITAS LTD · Mar 19, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how a supplement made from lentil protein affects blood pressure, blood vessel function, and exercise performance in healthy adults. The researchers want to understand if this lentil protein is safe to use and how different amounts of it might help with things like lowering blood pressure and improving exercise ability.

To be eligible for the study, participants should be healthy males and females aged 18 to 45 who are not taking medications or supplements that could interfere with the trial. They should also agree to keep their diet and exercise routines steady during the study. Participants will wear a device that tracks their activity for the duration of the trial. It’s important to note that those with certain health conditions, allergies, or who are pregnant or breastfeeding cannot participate. If you decide to join, you can expect to follow specific guidelines and provide feedback on your experience with the lentil protein supplement.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Willing to provide written and dated informed consent to participate in the study.
• • Willing and able to comply with the protocol.
• • Are not on any medication, or supplements which would impact the trial in the opinions of the investigator or Sponsor.
• • Male or female between 18 and 45 years of age (18.5 kg/m2 ≥ BMI \< 30 kg/m2).
• • Comply with ACSM guidelines for physical activity.
• • Have not participated in a clinical trial within the past month and agree to not participate in another clinical trial during the study period.
• • Agree to not significantly alter diet or exercise routine during the trial period.
• • Willing to wear a wearable device continuously for the duration of the study
• Exclusion Criteria:
• • Subjects having a known allergy or hypersensitivity to any of the ingredients in the investigational products.
• • Subjects with a history of alcohol and/or other drug abuse in the past year.
• • Has performed strenuous exercise (rating of perceived exertion ≥ 13) ≤ 48 hours before laboratory visit (Borg, 1982).
• • Consuming \>14 alcoholic drinks per week or \> 2 drinks/day in the 48 hours preceding a clinic visit.
• • Active smokers, nicotine use or vaping
• • Subjects suffering from a sleep disorder and/or who have a known history of (or was being treated for) clinical depression, eating disorder(s) or any other psychiatric condition(s) that might put the subject at risk and/or confounded the results of the study.
• • Subjects with a history of being diagnosed with phenylketonuria or another disease affecting amino acid metabolism (i.e., maple syrup urine disease, etc.).
• • Subjects with an elevated resting heart rate (\>100 bpm) or blood pressure (systolic BP \>140 mmHg or diastolic BP \>90 mmHg).
• • Pregnant or lactating women
• • Presentation of orthostatic hypotension during the screening and familiarisation study visit
• • Any condition which in the opinion of the investigator makes the participant unsuitable for inclusion.